Table 4.
Balance check propensity score weighted baseline measures
| Variable | Test cohort | Control cohort | Odds ratio (difference) (test vs. control) | ||
|---|---|---|---|---|---|
| (GA to FTY) | (GA only) | Mean | 95 % CI | p value | |
| Age group, years (%) | 0.2228 | ||||
| 18–34 | 7.1 | 8.7 | |||
| 35–44 | 19.3 | 22.8 | |||
| 45–54 | 36.2 | 34.7 | |||
| 55+ | 37.4 | 33.8 | |||
| Female gender (%) | 80.7 | 76.8 | 0.09 | ||
| Plan type (%) | 0.23 | ||||
| Fee for service | 80.5 | 83.0 | |||
| HMO and POS capitation | 19.5 | 17.0 | |||
| Region (%) | 0.87 | ||||
| Northeast | 19.3 | 19.1 | |||
| North central | 26.3 | 28.1 | |||
| South | 31.2 | 31.0 | |||
| West | 23.2 | 21.8 | |||
| Medication burden, meana | 7.90 | 7.35 | 0.54 | 0.01, 1.08 | 0.05 |
| Patients with MRI service (%) | 50.7 | 48.8 | 1.08 | 0.87, 1.33 | 0.49 |
| Patients with relapse (%) | 14.4 | 14.9 | 0.97 | 0.71, 1.30 | 0.82 |
| MS symptoms (%) | |||||
| Pain | 49.4 | 43.2 | 1.28 | 1.04, 1.59 | 0.02 |
| Depression | 15.3 | 14.4 | 1.07 | 0.80, 1.44 | 0.64 |
| Fatigue | 12.5 | 13.0 | 0.95 | 0.69, 1.31 | 0.78 |
| Walking (gait), balance, coordination problems | 12.5 | 10.9 | 1.17 | 0.85, 1.61 | 0.34 |
| Headache | 9.7 | 10.2 | 0.95 | 0.66, 1.35 | 0.76 |
| Bladder dysfunction | 9.2 | 9.7 | 0.94 | 0.65, 1.35 | 0.73 |
| Other emotional changes | 10.7 | 9.4 | 1.16 | 0.83, 1.64 | 0.39 |
| Numbness | 11.0 | 9.0 | 1.25 | 0.89, 1.75 | 0.20 |
| Others | 36.4 | 33.7 | 1.12 | 0.90, 1.40 | 0.29 |
| Modified PDC groupb | |||||
| <50 % | 10.7 | 9.9 | 0.84 | ||
| 50 to ≤80 % | 17.6 | 18.4 | |||
| ≥80 % | 71.8 | 71.7 | |||
PDC proportion of days covered, MS multiple sclerosis, MRI magnetic resonance imaging, HMO Health Maintenance Organization, POS point of service, GA glatiramer acetate, FTY fingolimod, PDC proportion of days covered
aExcluding DMTs
bModified PDC is calculated by [total Rx days of supply – max (0, (estimated next Tx date - study end date))] / (index date – date of first GA in baseline period)